Copyright
©The Author(s) 2024.
World J Diabetes. Jun 15, 2024; 15(6): 1060-1069
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1060
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1060
Type of drug | Example in use | BCC acting in a similar or related way | Ref. |
Biguanides | Metformin | Boron-containing biguanides have been synthesized and some have shown biological effects. Some BCC is being used in biomaterials for metformin release | Anderson et al[59], 1995; Ghosh et al[60], 1998; Lai et al[61], 2023 |
GLP-1 receptor agonist | Exenatide | No BCC has been designed with a structural analogy to known GLP-1 agonists. However, some BCC seems to be able to modify the incretins serum levels | Das et al[9], 2022; Ri et al[7], 2023 |
DPP-IV inhibitors | Sitagliptin | Dutogliptin, talabostat, PC06R58, and PC06R108 are potent uncompetitive DPP-IV inhibitors | Wu et al[55], 2021; Prajapati et al[62], 2024 |
SGLT2 inhibitors | Dapagliflozin | DX-B-DA, a fluorophore-dapagliflozin dyad has been tested as theranostic agent. It can bind the SGLT2 | Yu et al[63], 2021 |
Sulfonylureas | Glibenclamide | Glibenclamide-BCC acts as a high-affinity blocker of pancreatic β-cell KATP currents. Non-specific binding limited its use | Zünkler et al[64], 2004 |
α-glucosidase inhibitor | Acarbose | Some azaborininones exhibit moderate to good inhibitory effects against glucosidase to acarbose used as a reference standard | Mphahlele et al[65], 2021 |
Insulin | Insulin | Several BCC result in changes in insulin serum concentrations. Boric acid and phenylboronic acids diminish the increase of insulin release (and the total weight of visceral fat) in rats exposed to a high-fat diet and streptozotocin. The insulin release could be controlled by complexes with boronic acids | López-Cabrera et al[42], 2018; Banach et al[21], 2021; Kikuchi et al[66], 2021 |
- Citation: Soriano-Ursúa MA, Cordova-Chávez RI, Farfan-García ED, Kabalka G. Boron-containing compounds as labels, drugs, and theranostic agents for diabetes and its complications. World J Diabetes 2024; 15(6): 1060-1069
- URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1060.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1060